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Abstract
Background: One of the most critical problems about antimicrobial therapy is the increasing resistance to
antibiotics. Previous studies have shown that there is a direct relation between erroneous prescription, dosage, route,
duration of the therapy and the antibiotics resistance. Other important point is the uncertainty about the quality of
the prescribed medicines. Some physicians believe that generic drugs are not as effective as innovator ones, so it is
very important to have evidence that shows that all commercialized drugs are suitable for therapeutic use.
Methods: Microbial assays were used to establish the potency, the Minimal Inhibitory Concentrations (MICs), the
Minimal Bactericidal Concentration (MBCs), the critical concentrations, and the production of spontaneous mutants
that are resistant to vancomycin.
Results: The microbial assay was validated in order to determine the Vancomycin potency of the tasted samples.
All the products showed that have potency values between 90 - 115% (USP requirement). The products behave
similarly because the MICs, The MBCs, the critical concentrations, the critical concentrations ratios between
standard and samples, and the production of spontaneous mutants don’t have significant differences.
Conclusions: All products analyzed by microbiological tests, show that both trademarks and generics do not have
statistical variability and the answer of antimicrobial activity Show also that they are pharmaceutical equivalents.
Background
Pharmaceutical products, especially antibiotics, must com-
ply with standards of quality, efficacy and reliability, attri-
butes that are determined by various authorities [[1,2], and
[3]]. A discussion about the quality and efficacy of generic
antibiotics has taken place in recent decades. This discus-
sion has included presentations in congress and research
articles in which the authors have shown that some pro-
ducts do not meet regulatory standards [4,5] and that their
behavior is not similar in animal models [6,7]
Some antibiotics must be analyzed using biological
assays (e.g., penicillin, amikacyn, vancomycin, and neo-
mycin) [2]. These products are measured by their
potency or biological activity compared against an
international standard. Therefore, the commercial pro-
ducts must be similar in composition to the international
reference standard [7]. With antibiotics like vancomycin,
if the commercial products do not fulfill the require-
ments of pharmacopeia, their behavior and performance
could put a patient’s health in danger.
Biological assays and other analytical procedures must
be validated before they are applied in the analysis of the
content of the antibiotic under study because, otherwise,
neither the information or data generated nor conclusions
obtained will be reliable [3]. Our worry arises from the
fact that some researchers confuse a “gold standard” with
an international reference standard for quantification. A
gold standard is something that is a defined commercial
product used as reference of performance in comparative
studies. It is not a reference standard, but another com-
mercial product with its own variation. Gold standards are
established for purposes of bioequivalence and bioavail-
ability studies [2], but in the case of IV antibiotics, the
bioavailability is 100%, and therefore, pharmacodynamic
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Our group has been focusing on developing validated
techniques using proper international reference standards
to evaluate the content or potency of commercial antibio-
tics. These techniques can be used in performance studies
like those for the determination of a Minimal Inhibitory
Concentration (MIC), Minimal Lethal Concentration, Cri-
tical Concentration and production of Spontaneous
Mutants [8,9].
This paper presents the results for the evaluation of
commercial products of vancomycin to describe some
issues that are important in the evaluation of antibiotics.
Methods
Microorganisms
THE UNITED STATES PHARMACOPOEIA XXVII
states that spores of Bacillus subtilis ATCC 6633 are the
source of this microorganism used to develop a microbio-
logical assay for evaluating the potencies of vancomycin
products. For MIC and MBC studies, we used Acinetobac-
ter baumanii strains 59, 139, 147 and 173, Enterococcus
gallinarum, Streptococcus faecalis ATC 29212, a nosoco-
mial strain 319623 and a vancomycin-sensitive strain,
Escherichia coli strains 39, 50 and 69, Klebsiella pneumo-
niae strains 1, 43, 63, 65 and 207, Pseudomonas aeruginosa
strains 42, 74, 151, 157, and HE1, Staphylococcus aureus
strains 287, 291 and ATCC 25923, and Morganella morga-
nii HE2. All of the microorganisms were grown in Mueller
Hinton (MH) broth (incubated at 35°C for 24 h). Each
strain was then plated on MH agar to obtain isolated colo-
nies, which were then used to make larger cultures in MH
medium. The cultures were harvested with cryopreserva-
tion broth. A portion of each was kept in a cryovial at
-70°C, and the other portion was used to prepare a sus-
pension with 25% transmittance at 600 nm (25%T) to
develop in vitro assays. These suspensions were kept in
cryovials at - 70°C.
Analytical Bioassay
An analytical bioassay was established and validated for
vancomycin. First, the proper concentration range was
determined, and then the linearity, precision, specificity
and stability of the compound in question were assessed
[2,3]. All of the samples were evaluated with this analyti-
cal bioassay under the chosen conditions.
Minimal Inhibitory Concentration (MIC) and Minimal
Bactericidal Concentration (MBC)
Assays to assess these parameters were developed in two
parts. (1) Preparation of inocula: the number of colony
forming units (CFUs) was determined for each suspen-
sion at 25%T to prepare inocula of 1-5 × 10
6 CFUs/ml.
(2) M I Ca n dM B Cd e t e r m i n a t i o nb ym i c r o - d i l u t i o n :
samples were diluted to 2 mg/ml for evaluation. Using a
multichannel pipette, 100 μl Mueller Hinton Broth was
placed in each well of a 96-well ELISA plate, with 200 μl
in column 12. Next, 100 μl of the antibiotic solution
(2 mg/ml) was placed in the first column and thoroughly
mixed by pipetting. From these wells, 100 μl was added
to the second column and mixed, and this procedure was
repeated up to column 10, after which the 100-μl portion
was discarded. Columns 11 and 12 were positive and
negative controls, respectively. Each row (A to H) repre-
sented a different sample to be analyzed. Each inoculum
(100 μl) was then pipetted into each microplate, which
was incubated at 37°C for 24 h. Growth in the wells was
assessed. The lowest dilution showing no growth, the
first dilution with growth, and the two controls were pla-
ted onto MH agar. The MIC was defined as the lowest
dilution that showed no growth on the ELISA plate but
showed growth on MH agar. The MBC was defined as
the lowest dilution that did not show growth on either
the ELISA plate or MH agar [10].
Critical Concentration (CC)
The CC was determined similarly to the analytical
bioassay. The inocula for MIC and MBC determinations
and two-fold serial dilutions of each sample from 993 to
31,03 μg/ml were used (The batch of Vancomycin USP
standard has a potency of 99300 μg per vial). The halo
of inhibition was measured, and the crown length (Χ)
was calculated (the inhibition halo diameter minus the
reservoir diameter divided by 2). The log concentration
vs. Χ
2 was plotted, and a linear regression (y = mx + b)
was applied. The y-intercept (b) is equivalent to the log
of the CC [10].
Spontaneous mutants
Spontaneous mutation was analyzed similarly to the
analytical bioassay. Again, the inocula for the MIC and
MBC determinations were used. Specific microorgan-
isms and dilutions were selected after determinations of
critical concentrations. On each plate, a dilution of the
USP standard and samples of the same concentration
were used.
Samples
Commercial products purchased from the pharmacies of
different hospitals in Bogotá, D. C. Colombia, were ana-
lyzed. They included trademarked products and generic
products of vancomycin. All of the samples had declared
contents of 500mg. They were all diluted in sterile water
in 100 ml volumetric flasks. The solutions were divided
into 5-ml fractions for storage at -70°C and were diluted
to 1 mg/ml to develop the analytical bioassays.
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All the assays were performed three times, and the sta-
tistical tool of Microsoft Excel




The United Stated Pharmacopoeia XXVII recommends
Bacillus subtilis ATCC 6633 as the biological organism
to use to develop the analytical bioassay for vancomycin
products. Figure 1 shows the results of this bioassay.
Determination of concentration range, incubation time and
culture medium pH
Ten concentrations were used to determine the concentra-
tion range (two-fold dilutions from 1005 to 1.96 μg/ml,
because this batch of Vancomycin USP standard has a
potency of 100500 μg/vial). Table 1 shows that the best
linearity was in the range between C3 and C8 (251.25 to
7.85 μg/ml) (R
2 = 0.9907, Figure 2).
The assay required an 8 to 10 h incubation time at 37°C.
This incubation is shorter than many common assays,
which require between 18 and 24 h.
The results for Vancomycin show that a pH of 6.4 or
6.5 is optimal because growth was abundant and homo-
genous, and inhibition haloes were well defined at this
pH (Table 2).
Linearity
In Tables 3 and 4, the concentration of antibiotic corre-
lates well with the diameter of the zone of inhibition.
From this point on, the selected concentrations will be
designated C1 to C6 for clarity.
Figure 1 Bioassay of Vancomycin (USP standard) against
Bacillus subtilis ATCC 6633.
Table 1 Evaluation of the range of concentrations for
Vancomycin (USP standard)
Concentration Range Equation
From To Slope Intercept R
2
C1 C6 2.462680435 6.415123505 0.996221756
C2 C7 2.324635129 7.259328533 0.989384179
C3 C8 2.270224777 7.362386326 0.990682625
C4 C9 2.367915749 6.864768679 0.98750859
Cited on page 6
Figure 2 Calibration curve of Vancomycin (USP standard) used
to evaluate the linearity of the optimal concentration range.
Table 2 Evaluation of the pH effect on linearity
pH Equation R
2 Incubation Time
5.4 y = 1.8463x + 14.882 0.9806 8 hours
5.9 y = 2.3895x + 19.128 0.9898 8 hours
6.4 y = 1.5517x + 11.817 0.9977 8 hours
6.5 y = 2.134x + 7.4113 0.9975 8 hours
7 y = 1.7824 + 11.212 0.9794 9 hours
7.5 y = 1.875x + 11.009 0.9663 10 hours
8 y = 2.3651x + 9.3311 0.9763 11 hours
Cited on page 6.
Table 3 Evaluation of the linearity of Vancomycin
Test HYPOTHESIS Experimental t Theoretical t Decision
Slope H0:m=0
H1:m≠0
19.7 2.120 Reject H0
Intercept H0:b=0
H1:b≠0
125.3 2.120 Reject H0
Correlation H0:R=0
H1:R≠ 0
67.5 2.120 Reject H0
Cited on page 6.
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The reproducibility and between-day precision of our
assays were evaluated in several ways. Reproducibility
was studied by determining the coefficient of variation,
which was less than 1% and was acceptable for analytical
assays in the pharmaceutical industry (Table 5).
The between-day precision was also analyzed. Analysis
of variance (ANOVA) showed that, for the antibiotic
evaluated, the results of assays performed on different
days did not significantly differ (Table 6).
Stability
The stability of each compound during the experimental
period was verified. Solutions of vancomycin in water
and phosphate buffer, pH 4.5 (1005 μg/ml; USP Stan-
dard), were incubated at 37°C, 18°C and 4°C, and sam-
ples were taken after 24, 48, and 86 hours or seven and
fifteen days of incubation. The samples (Vancomycin
Standard Solution) under different treatments, were
diluted fromC1 to C6 to perform the relation Log Con-
centration vs. Halo Diameter Inhibition, and the results
were plotted and compared to reveal any reduction in
antibiotic activity (i.e., a decrease in the diameter of the
zone of inhibition).
From the equation y = mx + b,w h e r ey represents the
inhibition zone diameter and x represents the log of the
concentration, changes in the value of b indicate changes
in activity. If there is no change in the intercept, the anti-
biotic is stable. If the value of b decreases, this trend indi-
cates instability or a loss of activity.
The solutions showed a slight decrease in the inter-
cept values after 24 h of at each storage temperature
(Tables 7 and 8). From this result, it appears that the
molecule remained stable during our assays (48 hours at
37°C). Therefore, the assay results reflect the exact
potency of the product.
Specificity
To test specificity, solutions of the antibiotics were incu-
bated at 50°C. The vancomycin solutions lost a small
amount of activity (3% to 4%) after 15 days, but after 30
days, there was no longer any activity, meaning that
vancomycin was the only molecule in solution responsi-
ble for the antimicrobial activity (Table 9).
Sample analysis
The samples were analyzed with the previously validated
assay. The results were quantified using the statistical
method described by Hewitt (1977). Table 10 shows the
content of vancomycin in the samples purchased, and in
each case, the values fulfill the criteria laid out by USP
XXV II for intravenous vancomycin: “...Contents no
less than 90% and no more than 115% of Vancomy-
cin, calculated on anhydrous base of the quantity
registered of Vancomycin”.
Minimal inhibitory and bactericidal concentrations
Using the previously described methods, the samples
were analyzed in groups of seven per plate, and each
plate was inoculated with a single bacterial strain. The
first row of the plate contained the USP standard; the
other seven rows contained the samples. Figure 3 shows
the results for vancomycin products. The plates showed
the same performance for the standard as for the
samples.
Growth was inhibited at the same concentration of each
sample. After transfer onto MH agar, there was no growth
in concentrations C1 to C5 or C12, but there was growth
in C6 to C11. This result means that the antibiotic has an
Table 4 Regression analysis by analysis of variance (ANOVA)
Test HYPOTHESIS Experimental t Theoretical t Decision
Regression H0: There is no regression
H1: There is regression
146.6 4.670 Reject H0
Deviation from Linearity H0: There is no deviation from linearity
H1: There is a deviation from linearity
-3.0 3.71 Accept H0
Cited on page 6.




251.25 165.63 62.85 31.41 15.70 7.85
Standard
deviation
0.096 0.076 0.237 0.084 0.100 0.270
Variance
Coefficient (%)
0.4759 0.408422 1.4576 0.559623 0.7061 2.2425
Variance (S
2) 0.0092 0.00583 0.0113 0.00707 0.0099 0.01213
Sum (S
2) 0.05544
Cited on page 6.
Table 6 ANOVA of the between-day precision of assays
using Vancomycin
Concentration Experimental F Theoretical F Decision
C1 0.041 4.96 Accept H0
C2 0.047 4.96 Accept H0
C3 0.069 4.96 Accept H0
C4 0.093 4.96 Accept H0
C5 0.128 4.96 Accept H0
C6 0.182 4.96 Accept H0
Cited on page 6.
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and for all the samples. For all of the samples, using all of
the microorganisms evaluated, the results showed that the
samples had the same performances at each repetition of
the assay (Table 11 includes results for only some samples
as an illustration).
Critical concentration (CC)
The CC is the minimum concentration that inhibits
microorganism growth. It occurs at the limit of the inhi-
bition halo. It is a measure of a microorganism’ss e n s i -
tivity and can be different from the MIC, which is
determined under different conditions. The CC can be
defined mathematically as Ln(CC) = Ln(CO)-X
2/DTO,
where CC is the critical concentration, CO is the anti-
biotic concentration in the reservoir, X is the length of
the crown (see above), D is the diffusion coefficient, and
TO is the critical time. The intercept of a plot of Ln
(CO) vs. X
2 is the Ln of CC [7].
Figure 4 shows the different behaviors of the microor-
ganisms tested with the vancomycin standard. In Figures
4A and 4B, the microorganisms exhibited growth of
spontaneous mutants. Figure 4C shows a microorganism
resistant to vancomycin, and, finally, Figures 4D, E and
4F correspond to microorganisms with well-defined
haloes, allowing for a comparison of the performances
of the products tested for development. A well-defined
inhibition halo was the selection criterion for evaluating
CCs. For the CC assays, E. faecalis, E. faecalis ATCC
29212, E. faecalis 319623, A. baumanii 59, E. galli-
narum, P. aeruginosa 43 and 74, S. aureus 281, 291 and
ATCC 25923 were selected. Figure 5 shows the correla-
tion of X
2 with the log of antibiotic concentration. The
regression equation is y= 0.0353x + 0.9297, and b is
therefore 0.9287. The CC is equivalent to antilog
(0.9297), i.e., 8.506 μg/ml.
The CC values for the different vancomycin products
showed no significant differences, meaning that the pro-
ducts behaved in similar ways against the different
microorganisms tested (Table 12). On this basis, the
generic products meet all of the quality standards
applied to the pharmaceutical products and perform as
well as the newest versions of these products.
In addition, the ratio between the sample CCs and stan-
dard CCs are similar to the ratios of antibiotic contents. In
other words, all samples perform the same with regard to
their antimicrobial activities in vitro (Table 13).
Spontaneous mutants
It was noted in the previous assays that some strains pro-
duced spontaneous mutants (Figure 4A), as indicated by
the appearance of colonies within the inhibition halo.
Therefore, an assay to assess spontaneous mutation was
developed with appropriate concentrations of antibiotics.
Each experimental setup included an agar plate inoculated
with a test strain. Of the six reservoirs, two contained
standard solutions and the other four contained sample
solutions. The numbers of mutants produced by the stan-
dard and sample solutions were counted after incubation.
For the spontaneous mutant assays, the strains selected
were S. aureus 291 as a control strain (showing no pro-
duction of spontaneous mutants) and A. baumanii 54 and
Table 7 Stability of Vancomycin in water for injection at 4°C, 18°C and 37°C
Time 4°C 18°C 37°C
Slope Intercept R
2 Slope Intercept R
2 Slope Intercept R
2
0 h 1.5177 12.556 0.9913 1.5177 12.556 0.9913 1.5177 12.556 0.9913
24 h 1.5305 12.543 0.9908 1.5241 12.518 0.9916 1.5063 12.5210 0.9900
48 h 1.522 12.544 0.9919 1.518 12.501 0.9926 1.4936 12.495 0.9924
86 h 1.5224 12.509 0.9916 1.5178 12.461 0.9924 1.4981 12.4720 0.9928
7 days 1.5165 12.4780 0.9919 1.5217 12.342 0.9935 1.4742 12.3040 0.9904
15 days 1.5247 12.3460 0.9921 1.5041 12.273 0.9923 1.4425 12.1980 0.9916
Cited on page 7.
Table 8 Stability of Vancomycin in phosphate buffer, pH 4
Time 4°C 18°C 37°C
Slope Intercept R
2 Slope Intercept R
2 Slope Intercept R
2
0 h 1.4807 12.799 0.9916 1.4807 12.799 0.9916 1.4807 12.799 0.9916
24 h 1.4910 12.7640 0.9917 1.4833 12.764 0.9917 1.5195 12.5150 0.9916
48 h 1.487 12.733 0.9924 1.4747 12.716 0.9928 1.509 12.497 0.9922
86 h 1.4787 12.7260 0.9933 1.4701 12.689 0.9927 1.5057 12.4700 0.9915
7 days 1.4804 12.6510 0.9925 1.4766 12.571 0.9931 1.4966 12.3800 0.9922
15 days 1.4826 12.5170 0.9937 1.4566 12.505 0.9932 1.4887 12.2510 0.9926
Cited on page 7.
Diaz et al. BMC Clinical Pharmacology 2011, 11:9
http://www.biomedcentral.com/1472-6904/11/9
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analysis, the results (Table 14) showed no significant dif-
ferences between the products in the production of spon-
taneous mutants for any of the strains tested (Figure 6).
Discussion
Despite the fact that USP Pharmacopoeia assesses the
bioassay conditions for vancomycin evaluation, the
bioassay was validated following the suggestions of the
Table 9 Stability of Vancomycin in phosphate buffer, pH 4
Time Phosphate Buffer, pH 4.5 Water For Injection
Slope Intercept R
2 Slope Intercept R
2
0 h 1.4807 12.799 0.9916 1.5177 12.556 0.9913
24 h 1.5268 12.4310 0.9909 1.5059 12.4640 0.9905
48 h 1.4924 12.479 0.9912 1.4907 12.409 0.993
86 h 1.4894 12.4530 0.9914 1.4939 12.3520 0.9930
7 days 1.4515 12.3970 0.9869 1.4569 12.3230 0.9897
15 days 1.4226 12.3060 0.9855 1.4343 12.2370 0.9907
30 days NDA NDA
ND: Non detectable activity.
Cited on page 7.

































Cited on pages 7 and 9.
Figure 3 MIC assays of vancomycin products against K.
pneumoniae 63.
Table 11 Determination of MICs and MBCs for
Vancomycin (USP standard)
Microorganism MIC (μg/ml) MBC (μg/ml)
Std M1 M2 Std M1 M2
A. baumanii 59 62.06 62.06 62.06 124.13 124.13 124.13
A. baumanii 139 124.13 124.13 124.13 248.25 248.25 248.25
A. baumanii 147 993 993 993 ND ND ND
A. baumanii 173 62.06 62.06 62.06 124.13 124.13 124.13
E. faecalis 1.93 1.93 1.93 3.88 3.88 3.88
E. faecalis ATCC 29212 7.76 7.76 7.76 15.52 15.52 15.52
E. faecalis 319623 62.06 62.06 62.06 124.13 124.13 124.13
E. gallinarum ND ND ND 124.13 124.13 124.13
E. coli 39 124.13 124.13 124.13 248.25 248.25 248.25
E. coli 50 124.13 124.13 124.13 248.25 248.25 248.25
E. coli 69 496.50 496.50 496.50 993.00 993.00 993.00
K. pneumoniae 1 ND ND ND 496.50 496.50 496.50
K. pneumoniae 43 496.5 496.5 496.5 993.00 993.00 993.00
K. pneumoniae 63 993.00 993.00 993.00 ND ND ND
K. pneumoniae 65 993.00 993.00 993.00 ND ND ND
K. pneumoniae 207 496.00 496.00 496.00 993.00 993.00 993.00
Ps. aeruginosa 42 1.94 1.94 1.94 3.88 3.88 3.88
Ps. aeruginosa 74 1.94 1.94 1.94 3.88 3.88 3.88
Ps. aeruginosa 151 993.00 993.00 993.00 ND ND ND
Ps. aeruginosa 157 993.00 993.00 993.00 ND ND ND
Ps. aeruginosa HE1 993.00 993.00 993.00 ND ND ND
St. Aureus 287 1.94 1.94 1.94 3.88 3.88 3.88
St. Aureus 291 1.94 1.94 1.94 3.88 3.88 3.88
St. Aureus ATCC 25923 1.94 1.94 1.94 3.88 3.88 3.88
M. morganii HE2 496.50 496.50 496.50 993.00 993.00 993.00
Cited on pages 7 and 9.
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results concerning the sample contents. The experiment
to evaluate assay performance showed that it fulfilled
the assay requirements (linearity, repeatability, preci-
sion). In the assay, the best linearity was shown over the
range of 251.25 μg/ml to 7.85 μg/ml, i.e., the correlation
was the highest (R
2 = 0.9907). The reproducibility and
between-day precision of both assays had coefficients of
variation less than 1%, and ANOVA showed no signifi-
cant differences at any concentration. Antibiotic activity
remained stable over the course of the assay at the
selected temperature. Finally, the inhibition assay results
were due only to the molecules evaluated. In conclusion,
the assay was exact and accurate with reproducible
results.
Our results were generally similar to those of Zuluaga
et al. (2009), but with some differences. Zuluaga et al.
(2009) proposed a comparison of the performances of
all samples by linear correlation against the performance
of the original compound to determine pharmaceutical
equivalence. This approach is problematic because the
commercial products exhibit some differences in their
potency. The USP Pharmacopoeia XXVII states “...Con-
t e n t sn ol e s st h a n9 0 %a n dn om o r et h a n1 1 5 %o f
Vancomycin, calculated on anhydrous base of the
quantity registered of Vancomycin”,a r ea c c e p t a b l e .
Therefore, if we use a reference element for which there
is uncertainty about its content, a sample could be
assessed against different potencies. For example, if the
commercial sample has 90% of the potency of Vancomy-
cin, the potency of the sample under study will be over-
valued, but if the reference sample has 115% of the
potency, the sample under study will be undervalued.
Finally, we strongly recommend that an antibiotic must
be evaluated against an international reference standard
by established and validated bioassays using an appro-
priate test microorganism and conditions. Then, the
conclusions about the samples contents will be certain.
Analyses of commercial versions of the antibiotics
tested (brand-name and generic products) indicate that
all of the samples can be considered pharmaceutical
equivalents because they all fulfill the standards of the
USP Pharmacopoeia (Table 10). In the study by Zuluaga
Figure 4 Zones of inhibition produced by Vancomycin against (A) E. gallinarum,( B )A. baumanii 54, (C) K. pneumoniae 1, (D) P.
aeruginosa 43, (E) P. aeruginosa 74 and (F) S. aureus 291.
Figure 5 Determination of critical concentration of Vancomycin
against P. aeruginosa 74.
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Page 7 of 10Table 12 Critical concentrations (μg/ml) of different samples of Vancomycin against various microorganisms.
Sample E. f. E. f. 29212 E. f. 319623 A. b.5 9 E. g. P. a.4 3 P. a.7 4 S. a. 281 S. a. 291 S. a. 25923
Standard 13.251 14.098 26.733 7.712 14.725 10.932 8.586 9.951 12.473 13.108
M2 13.332 14.173 26.826 7.735 14.850 10.988 8.646 10.044 12.558 13.164
M3 13.050 14.170 26.505 7.759 14.993 10.977 8.745 10.032 12.764 13.410
M4 13.166 14.041 26.630 7.670 15.076 10.870 8.635 9.991 12.682 13.202
M5 12.961 14.566 26.160 8.305 14.798 11.716 9.474 10.941 13.753 14.662
M6 14.495 13.338 28.017 7.355 13.974 10.308 8.016 9.280 11.725 12.324
M7 12.523 14.237 26.540 7.856 16.029 12.348 9.666 11.143 14.076 14.729
M8 13.441 13.627 27.530 8.053 15.008 11.248 8.903 10.138 13.220 13.440
M13 13.052 14.193 26.574 8.003 14.955 11.146 8.908 10.306 12.713 13.489
M14 13.792 15.904 28.612 8.481 15.291 12.621 9.897 11.480 14.454 15.286
M15 13.791 15.673 27.431 8.190 15.700 11.969 9.500 11.015 13.820 14.539
M16 13.483 14.326 26.535 7.698 14.991 10.743 8.458 9.795 12.363 12.986
M17 13.720 15.128 27.261 8.068 15.794 12.163 9.519 11.006 13.786 14.510
M18 13.697 14.790 26.915 7.720 15.196 11.671 8.965 10.384 13.427 13.807
M20 13.568 14.405 27.117 7.660 14.535 10.760 8.506 9.835 12.249 12.886
M21 13.192 14.632 26.985 7.857 16.048 11.178 8.759 10.091 12.625 13.413
M22 14.067 13.946 26.536 7.774 15.571 11.309 8.741 10.057 12.769 13.437
M24 13.334 14.046 26.701 7.856 14.655 10.895 8.639 10.016 12.418 13.125
M26 13.882 14.592 26.519 7.638 15.409 11.116 8.739 10.038 12.671 13.299
M27 12.741 13.544 25.775 7.474 14.126 10.499 8.326 9.612 12.200 12.595
M29 13.571 14.008 26.770 8.274 15.281 11.105 9.143 10.404 12.998 13.887
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Table 13 Ratios of sample CC/standard CC for Vancomycin
SAMPLE MICROORGANISMS Ratio Median Potency
E. f. E. f. 29212 E. f. 319623 A. b.5 9 E. g. P. a.4 3 P. a.7 4 S. a. 281 S. a. 291 S. a. 25923
Standard
M2 1.006 1.005 1.003 1.003 1.008 1.005 1.007 1.009 1.007 1.004 1.006 0.995
M3 0.985 1.005 0.991 1.006 1.018 1.004 1.018 1.008 1.023 1.023 1.008 1.012
M4 0.994 0.996 0.996 0.995 1.024 0.994 1.006 1.004 1.017 1.007 1.003 1.005
M5 0.978 1.033 0.979 1.077 1.005 1.072 1.103 1.100 1.103 1.119 1.057 1.100
M6 1.094 0.946 1.048 0.954 0.949 0.943 0.934 0.933 0.940 0.940 0.968 0.936
M7 0.945 1.010 0.993 1.019 1.089 1.130 1.126 1.120 1.128 1.124 1.068 1.124
M8 1.014 0.967 1.030 1.044 1.019 1.029 1.037 1.019 1.060 1.025 1.024 1.032
M13 0.985 1.007 0.994 1.038 1.016 1.020 1.038 1.036 1.019 1.029 1.018 1.023
M14 1.041 1.128 1.070 1.100 1.038 1.155 1.153 1.154 1.159 1.166 1.116 1.150
M15 1.041 1.112 1.026 1.062 1.066 1.095 1.106 1.107 1.108 1.109 1.083 1.108
M16 1.018 1.016 0.993 0.998 1.018 0.983 0.985 0.984 0.991 0.991 0.998 0.986
M17 1.035 1.073 1.020 1.046 1.073 1.113 1.109 1.106 1.105 1.107 1.079 1.107
M18 1.034 1.049 1.007 1.001 1.032 1.068 1.044 1.044 1.076 1.053 1.041 1.047
M20 1.024 1.022 1.014 0.993 0.987 0.984 0.991 0.988 0.982 0.983 0.997 0.981
M21 0.996 1.038 1.009 1.019 1.090 1.023 1.020 1.014 1.012 1.023 1.024 1.019
M22 1.062 0.989 0.993 1.008 1.057 1.035 1.018 1.011 1.024 1.025 1.022 1.011
M24 1.006 0.996 0.999 1.019 0.995 0.997 1.006 1.006 0.996 1.001 1.002 1.003
M26 1.048 1.035 0.992 0.990 1.046 1.017 1.018 1.009 1.016 1.015 1.019 1.011
M27 0.962 0.961 0.964 0.969 0.959 0.960 0.970 0.966 0.978 0.961 0.965 0.961
M29 1.024 0.994 1.001 1.073 1.038 1.016 1.065 1.046 1.042 1.059 1.036 1.062
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Page 8 of 10et al. (2009), the performance of all samples was similar
to the innovator, and the results were accurate and
reproducible, which means that all of the producers of
this antibiotic are using similar parameters to manufac-
ture their products.
The MIC and MBC results obtained with different
pathogenic strains showed no differences between samples
(Tables10 and 11), which is probably because the samples
were pharmaceutical equivalents. We conclude that gen-
eric and novel products perform equally well. In other
words, the generic products evaluated in this study fulfill
the requirements to be considered for use in antimicrobial
therapy.
We also designed an assay to determine critical concen-
trations using a few selected strains to confirm that all of
the generic products evaluated were effective in antimicro-
bial therapy. The results showed no significant differences
among samples (Table 12). Moreover, the ratios between
the CC of the standard and those of the different samples
were similar to their potency levels (Tables 13).
Along the same lines, an assay was designed to deter-
mine the production of spontaneous mutants in diffu-
sion gel assays. The results again showed that all the
samples behaved similarly, leading us to conclude that
none of the samples studied markedly differ in their
antimicrobial activities. That is, generic and brand name
products that comply with the international specifica-
tions for manufacturing pharmaceutical products behave
similarly to novel products.
Our results are different from those of other studies
[5,6]. Those studies were conducted using the newest
product as a “standard of comparison,” but the research-
ers did not take into account that a commercial product
may have a range of content between 90% and 120%.
Consequently, there would be great variability in the
results with respect to the performance of the antibiotic.
For instance, if the novel drug product has a hypotheti-
cal content of 120% relative to the declared content on
the label, and the generic product has a hypothetical
content of 90%, then the effective content of the generic
product would be 75% (90/120) of the novel drug. This
scenario could produce misleading results because
although both products fulfill the content requirements,
the first is at the upper limit and the second at the
lower limit.
It has been proposed that generic antibiotics behave
differently from innovator products against pathogenic
microorganisms [5,6]. This is possible if the generic anti-
biotic does not fulfill the quality standards for that phar-
maceutical product (e.g., purity or content). For instance,
contaminants in generic drugs could interfere with their
antibiotic activities.
Vesga et al (2009) reported that none of the vancomy-
cin products have differences in in vitro assays; they had
Table 14 Spontaneous mutant production in the
diffusion gel assay for vancomycin products
Sample Mutants of A. baumanii 54 Mutants of E. gallinarum
Median s Median s
Standard 106.17 1.47 96.500 5.089
M2 111.00 1.00 100.667 2.082
M3 104.33 1.53 98.333 1.528
M4 106.67 2.08 104.667 5.686
M5 103.67 0.58 99.000 2.000
M6 109.00 1.00 96.000 2.000
M7 110.67 1.53 100.667 1.155
M8 108.67 1.53 98.667 1.155
M10 104.00 1.73 95.667 1.528
M12 110.67 1.53 93.333 2.517
M13 106.33 1.53 94.000 3.000
M14 106.67 2.52 101.000 1.000
M15 110.67 1.15 99.333 1.155
M17 105.33 1.15 93.667 3.786
M18 104.33 2.08 96.000 1.000
M20 109.33 1.53 100.667 0.577
M22 112.00 1.00 103.000 3.000
M24 105.33 1.53 96.000 1.000
M26 109.33 1.53 100.667 0.577
M27 112.00 1.00 103.000 3.000




Cited on page 9
Figure 6 Production of spontaneous vancomycin-resistant
mutants of E. gallinarum.
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Page 9 of 10no differences in potency, MIC or MBC. Also, in time-kill
curves and single-dose serum Pharmacokinetics (PK) in
infected mouse there were no differences. However, the
pharmacodynamic study had very odd results; the pro-
ducts tested did not behave like the innovator in vitro.
We think that these resultss h o u l db er e a n a l y z e do r
retested because at the lower concentration, the generics
have a better antimicrobial activity than the innovator,
but in the higher concentrations, these behaviors change.
T h ef r e ea n t i b i o t i ci nt h es e r u mi st h eo n l yc h e m i c a l
responsible for the antimicrobial activity and they
showed in the PK model that all of the antibiotics diffuse
into the blood in an equivalent way; so, they should
behave against the same microorganism in an equivalent
way.
Conclusions
All of the samples analyzed by standardized, microbiolo-
gical methods fulfill the requirements for content
according to USP XXVII. They all show the same anti-
microbial behavior because they have similar MIC, MBC
and CC values and produce similar numbers of mutants.
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